Nosocomial Infection
1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
1 programAn Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical PracticeN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstraZenecaAn Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice
Clinical Trials (1)
Total enrollment: 1,500 patients across 1 trials
NCT00864929AstraZenecaAn Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice
An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice
Start: Nov 2009Est. completion: Oct 20101,500 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.